Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Rating of “Moderate Buy” by Brokerages

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has earned an average rating of “Moderate Buy” from the thirteen brokerages that are presently covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $67.00.

NTLA has been the subject of a number of recent analyst reports. Wolfe Research began coverage on shares of Intellia Therapeutics in a report on Thursday, February 15th. They set a “peer perform” rating for the company. Canaccord Genuity Group increased their target price on shares of Intellia Therapeutics from $72.00 to $73.00 and gave the stock a “buy” rating in a report on Friday, February 23rd. The Goldman Sachs Group cut Intellia Therapeutics from a “buy” rating to a “neutral” rating and cut their target price for the stock from $136.00 to $32.00 in a research note on Friday, February 23rd. Finally, Wedbush reaffirmed a “neutral” rating and set a $29.00 price target on shares of Intellia Therapeutics in a research report on Tuesday, April 23rd.

Intellia Therapeutics Trading Up 5.9 %

Shares of NASDAQ:NTLA opened at $21.98 on Tuesday. The stock has a market capitalization of $2.12 billion, a P/E ratio of -4.06 and a beta of 1.77. The stock’s 50-day moving average price is $26.39 and its 200-day moving average price is $27.47. Intellia Therapeutics has a 12-month low of $19.37 and a 12-month high of $47.48.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, February 22nd. The company reported ($1.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.01. The business had revenue of ($1.92) million for the quarter, compared to analyst estimates of $15.10 million. Intellia Therapeutics had a negative return on equity of 43.91% and a negative net margin of 893.34%. During the same period last year, the company earned ($1.40) EPS. As a group, research analysts predict that Intellia Therapeutics will post -5.57 EPS for the current year.

Insiders Place Their Bets

In other news, EVP James Basta sold 2,297 shares of the business’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $32.99, for a total transaction of $75,778.03. Following the sale, the executive vice president now owns 81,571 shares in the company, valued at approximately $2,691,027.29. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 3.00% of the stock is owned by corporate insiders.

Institutional Trading of Intellia Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Blue Trust Inc. purchased a new stake in shares of Intellia Therapeutics in the fourth quarter worth $26,000. Signaturefd LLC boosted its stake in Intellia Therapeutics by 89.3% in the 4th quarter. Signaturefd LLC now owns 1,592 shares of the company’s stock worth $49,000 after purchasing an additional 751 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in Intellia Therapeutics by 95.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,263 shares of the company’s stock valued at $72,000 after purchasing an additional 1,108 shares during the last quarter. Daiwa Securities Group Inc. increased its stake in Intellia Therapeutics by 35.0% during the 4th quarter. Daiwa Securities Group Inc. now owns 3,056 shares of the company’s stock valued at $93,000 after purchasing an additional 793 shares in the last quarter. Finally, Spire Wealth Management raised its holdings in Intellia Therapeutics by 3,789.0% in the fourth quarter. Spire Wealth Management now owns 3,889 shares of the company’s stock worth $119,000 after buying an additional 3,789 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.